medigraphic.com

2010, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (1)

Acromegaly treatment with octreotide LAR in 42 cases

Gómez-Martínez G, Martínez-Delgado IA

Language: Spanish
References: 15
Page: 39-45
PDF size: 47.94 Kb.


ABSTRACT

Objective: to evaluate the efficacy of octreotide (OCT) LAR in patients with acromegaly.
Methods: observational, retrospective, transversal and descriptive study was done. Forty two patients with acromegaly (recently diagnosed and who have undergone surgery but not cured) followed up for 24 weeks were studied. There were 14 males (30 %) and 28 females (70 %) with an average age of 44 (range: 18-67 years). Dose adjustments of 10, 20 and 30 mg were made.
Results: OCT LAR was administered in 24 patients who had been operated without cure and in 18 newly diagnosed patients. At 24 weeks of treatment in those patients not operated, GHm decreased 56 % and IGF-1 decreased 30 %. In patients who were operated but not cured, GHm decreased 49 % and IGF-1 decreased 53 %. For microadenomas, GHm decreased 57.6 % and IGF-1 60 %. For macroadenomas, decrease was 50 % and 37 %, respectively. The efficacy of OCT LAR on microadenomas, success was achieved (total and partial) in 65 % of patients and in 28 % of patients with macroadenomas.
Conclusions: Patients with microadenomas and with lesser hypersomatotropinemia have a better response to treatment.


REFERENCES

  1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Rev 2004;25:102-152.

  2. Donangelo I, Melmed S. Treatment of acromegaly. Endocrine 2005;28:123-128.

  3. Vance ML, Laws ER Jr. Role of medical therapy in the management of acromegaly. Neurosurgery 2005;56:877-885.

  4. Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, et al. Gamma knife radiosurgery for acromegaly. Long-term experience. Clin Endocrinol 2006;64:588-595.

  5. Sociedad Mexicana de Nutrición y Endocrinología. Segundo Consenso Nacional de Acromegalia. Rev Endocrinol Nutr 2007;15;S7-S16.

  6. Martínez-Delgado I, Gómez-Martínez G. Acromegalia. Informe de 84 casos. Rev Med Inst Mex Seguro Soc 2008;46(3):311-314.

  7. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long term (Up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkege. J Clin Endocrinol Metab 2006;91: 1397-1403.

  8. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al; SMS995B2401 Study Group. A prospective, multicentre study to inves-tigate the efficacy, safety and tolerability of octreotide LAR en the primary therapy of patients with acromegaly. Clin Endocrinol 2007;66:859-868.

  9. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long term effects of depot long acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86: 2779.2786.

  10. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes- Lacroix F, Cournot M, et al. Long term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 2007;67:282-289.

  11. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 2006;64:342-351.

  12. Jallad R, Musolino N, Kodaira S, Cescati V, Bronstein M. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol 2007;67: 310-315.

  13. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-4410.

  14. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumour size. J Clin Endocrinol Metab 2002;87(4): 554-4563.

  15. JS Bevan. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-1863.




2020     |     www.medigraphic.com